Unnecessary imaging studies … it’s on the docs!

Here in the USA, about half the patients diagnosed with low-risk prostate cancer are still (apparently) being sent for “guideline-discordant” (i.e., unnecessary) bone scans and CT scans, … READ MORE …

Can PSMA PET scans replace the need for bone and CT scans?

A new review article suggests the possibility that radiolabeled prostate specific membrane antigens (PSMAs) and PET scans may, at some point in the not too distant future, replace bone and CT scans in diagnosis and monitoring of men with advanced forms of prostate cancer. … READ MORE …

Risk for fractures and fracture prevention among prostate cancer patients

An interesting new paper in BJU International has provided us with a somewhat different perspective on which patients with prostate cancer do and do not need preventive therapy (e.g., zoledronic acid/Zometa, dasatinib/Xgeva) to minimize risk for bone fractures. … READ MORE …

The role of CT scanning in assessment of progression of men with CRPC

A newly published paper in the journal Cancer seems to be implying that every man with castration-resistant prostate cancer who progresses from non-metastatic to metastatic status (based on a bone scan or other indicators) should also be given a CT scan because of risk for soft tissue metastasis. … READ MORE … >

Newer types of whole body scanning are likely to be significantly better than older bone scans, but …

A new report in the Journal of Nuclear Medicine has suggested that it may be time to start looking seriously at whether the combined [18F]NaF/[18F]FDG PET/CT scan may be significantly better than the traditional [99m]Tc bone scan in evaluation of risk for or the actual presence of metastasis in men with prostate cancer. … READ MORE …

> 40 percent of low-risk prostate cancer patients were getting inappropriate imaging tests

A new paper in JAMA Oncology has shown that between 2004 and 2007 nearly 45 percent of men initially diagnosed with low-risk prostate cancer were receiving unnecessary bone scans and CT scans in some regions of the USA. … READ MORE …

Use of bisphosphonate therapy in men on ADT in Ontario, Canada

According to a research letter published in the Journal of the American Medical Association, most men in Ontario, Canada, who have androgen deprivation therapy (ADT) for treatment of prostate cancer have not been receiving bisphosphonate or comparable therapy. … READ MORE …